Opportunistic Screening of High-Risk Breast Cancer Variants in Hospital Biobank Participants

Biobank data reuse for BRCA1/2/PALB2 variant screening, informing previously undiagnosed carriers

This Finnish pilot project evaluates the feasibility and impact of opportunistic screening for BRCA1, BRCA2, and PALB2 pathogenic variants in hospital biobank participants. Previously unidentified carriers are detected, and their notification leads to appropriate prophylactic management. The approach demonstrates that biobanks represent an effective secondary screening infrastructure for hereditary breast and ovarian cancer predispositions, without requiring prior oncogenetics consultation.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Opportunistic screening via biobanks is a promising public health approach for identifying BRCA predisposition carriers who do not meet traditional referral criteria. This Finnish model, based on broad prior consent, is potentially transferable to other countries with mature biobank infrastructures.

Clinical impact: 3/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 8/10